Francois Habersetzer

Summary

Country: France

Publications

  1. doi request reprint Synthetic anti-lipopolysaccharide peptides and hepatitis C virus infection
    Francois Habersetzer
    Inserm U1110, Institut de Virologie, 3 Rue Koeberle, 67000 Strasbourg, France
    Expert Opin Investig Drugs 22:853-62. 2013
  2. doi request reprint A poxvirus vaccine is safe, induces T-cell responses, and decreases viral load in patients with chronic hepatitis C
    Francois Habersetzer
    INSERM, Strasbourg, France Université de Strasbourg, Strasbourg, France
    Gastroenterology 141:890-899.e1-4. 2011
  3. doi request reprint Challenges for HCV vaccine development in HIV-HCV coinfection
    Mélanie Lambotin
    INSERM, U748, 67000 Strasbourg, France
    Expert Rev Vaccines 11:791-804. 2012
  4. doi request reprint Hepatitis C virus vaccines--progress and perspectives
    Catherine Fauvelle
    INSERM, U1110, Institut de Virologie, Strasbourg, France Université de Strasbourg, Strasbourg, France
    Microb Pathog 58:66-72. 2013
  5. pmc Hepatitis B virus mutations potentially conferring adefovir/tenofovir resistance in treatment-naive patients
    Rebecca Pastor
    Institut de Virologie, 3 Rue Koeberle, 67000 Strasbourg, France
    World J Gastroenterol 15:753-5. 2009
  6. pmc Adaptive immunity to hepatitis C virus
    Mirjam B Zeisel
    INSERM, U748, 3 Rue Koeberle, F 67000 Strasbourg, France E Mails M B Z S F K E R F H T F B
    Viruses 1:276-97. 2009
  7. ncbi request reprint GI-5005, a yeast vector vaccine expressing an NS3-core fusion protein for chronic HCV infection
    Francois Habersetzer
    Hopitaux Universitaires de Strasbourg, Service d Hepatogastroenterologie, Strasbourg, France
    Curr Opin Mol Ther 11:456-62. 2009
  8. doi request reprint Mutations that alter use of hepatitis C virus cell entry factors mediate escape from neutralizing antibodies
    Isabel Fofana
    INSERM, U748, Hopitaux Universitaires de Strasbourg, Strasbourg, France
    Gastroenterology 143:223-233.e9. 2012

Collaborators

Detail Information

Publications8

  1. doi request reprint Synthetic anti-lipopolysaccharide peptides and hepatitis C virus infection
    Francois Habersetzer
    Inserm U1110, Institut de Virologie, 3 Rue Koeberle, 67000 Strasbourg, France
    Expert Opin Investig Drugs 22:853-62. 2013
    ..Although antiviral therapy has been markedly improved by the licensing of direct-acting antivirals, safety, resistance, high costs and difficult-to-treat patients remain important challenges...
  2. doi request reprint A poxvirus vaccine is safe, induces T-cell responses, and decreases viral load in patients with chronic hepatitis C
    Francois Habersetzer
    INSERM, Strasbourg, France Université de Strasbourg, Strasbourg, France
    Gastroenterology 141:890-899.e1-4. 2011
    ..We performed a phase I clinical trial to assess the safety, immunogenicity, and early antiviral efficacy of TG4040 in patients with CHC...
  3. doi request reprint Challenges for HCV vaccine development in HIV-HCV coinfection
    Mélanie Lambotin
    INSERM, U748, 67000 Strasbourg, France
    Expert Rev Vaccines 11:791-804. 2012
    ..Here, the authors review the pathogenesis of hepatitis C in HIV-infected patients, with a focus on the impact of HIV on HCV-specific immune responses and discuss the challenges for vaccine development in HIV-HCV coinfection...
  4. doi request reprint Hepatitis C virus vaccines--progress and perspectives
    Catherine Fauvelle
    INSERM, U1110, Institut de Virologie, Strasbourg, France Université de Strasbourg, Strasbourg, France
    Microb Pathog 58:66-72. 2013
    ....
  5. pmc Hepatitis B virus mutations potentially conferring adefovir/tenofovir resistance in treatment-naive patients
    Rebecca Pastor
    Institut de Virologie, 3 Rue Koeberle, 67000 Strasbourg, France
    World J Gastroenterol 15:753-5. 2009
    ..Thus, mutations in untreated patients deserve cautious surveillance. These data indicate that mutations that can theoretically confer adefovir or tenofovir resistance may emerge in treatment-naive patients...
  6. pmc Adaptive immunity to hepatitis C virus
    Mirjam B Zeisel
    INSERM, U748, 3 Rue Koeberle, F 67000 Strasbourg, France E Mails M B Z S F K E R F H T F B
    Viruses 1:276-97. 2009
    ..Unravelling these important mechanisms of virus-host interaction will contribute to the development of novel strategies to prevent and control HCV infection...
  7. ncbi request reprint GI-5005, a yeast vector vaccine expressing an NS3-core fusion protein for chronic HCV infection
    Francois Habersetzer
    Hopitaux Universitaires de Strasbourg, Service d Hepatogastroenterologie, Strasbourg, France
    Curr Opin Mol Ther 11:456-62. 2009
    ....
  8. doi request reprint Mutations that alter use of hepatitis C virus cell entry factors mediate escape from neutralizing antibodies
    Isabel Fofana
    INSERM, U748, Hopitaux Universitaires de Strasbourg, Strasbourg, France
    Gastroenterology 143:223-233.e9. 2012
    ..We used acute infection of liver graft as a model to investigate the molecular mechanisms of viral evasion...